With OTC Cialis Rights, Sanofi Launches Latest Salvo In Consumer Sector Battle
This article was originally published in The Tan Sheet
Executive Summary
Sanofi gains rights from Eli Lilly & Co. to apply for OTC approval of Cialis in the U.S., Europe, Canada and Australia. Launching the first OTC product indicated for erectile dysfunction would mark another milestone in Sanofi CEO Chris Viebacher’s mission to move the firm into the neighborhood of global OTC leaders.
You may also be interested in...
Cialis Or Viagra Switch? Sanofi Survey, Pfizer Help Wanted Ad Could Be Signs
Viagra marketer Pfizer also could have nonprescription sales in sight as it recruits a "global sexual health" brand manager with responsibilities including shepherding market expansion through an Rx-to-OTC switch.
Cialis Or Viagra Switch? Sanofi Survey, Pfizer Help Wanted Ad Could Be Signs
Viagra marketer Pfizer also could have nonprescription sales in sight as it recruits a "global sexual health" brand manager with responsibilities including shepherding market expansion through an Rx-to-OTC switch.
Sanofi Creates Consumer Unit With Eye To Expansion
Former Bayer executive Alan Main tapped to lead Consumer HealthCare global business unit, which Sanofi will consider expanding through acquisitions after integrating OTC brands added in a recent swap with Boehringer Ingelheim.